GB8817743D0
(en)
|
1988-07-26 |
1988-09-01 |
Fujisawa Pharmaceutical Co |
Fr901228 substance & preparation thereof
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
JPH0764872A
(ja)
|
1993-08-26 |
1995-03-10 |
Fujitsu Ten Ltd |
データ記憶制御装置
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US5776905A
(en)
|
1996-08-08 |
1998-07-07 |
The Board Of Trustees Of The Leland Stamford Junior University |
Apoptotic regression of intimal vascular lesions
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
EP1010705A4
(en)
|
1997-09-02 |
2004-09-15 |
Sumitomo Pharma |
NEW CYCLIC TETRAPEPTIDE DERIVATIVES AND THEIR MEDICAL USE
|
JPH11335375A
(ja)
|
1998-05-20 |
1999-12-07 |
Mitsui Chem Inc |
ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
WO2001018171A2
(en)
|
1999-09-08 |
2001-03-15 |
Sloan-Kettering Institute For Cancer Research |
Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
PT1438966E
(pt)
|
1999-12-08 |
2007-05-31 |
Cyclacel Pharmaceuticals Inc |
Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
|
CA2317003A1
(en)
|
2000-02-28 |
2001-08-28 |
Hidenori Nakajima |
Gene expression potentiator
|
JP2001348340A
(ja)
|
2000-06-07 |
2001-12-18 |
Yamanouchi Pharmaceut Co Ltd |
ヒストン脱アセチル化酵素阻害剤
|
JP4810784B2
(ja)
|
2000-07-17 |
2011-11-09 |
アステラス製薬株式会社 |
還元型fk228およびその用途
|
AU2001285042A1
(en)
*
|
2000-08-18 |
2002-03-04 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
JP2004508049A
(ja)
|
2000-09-01 |
2004-03-18 |
藤沢薬品工業株式会社 |
Fr901228物質の製造法
|
AU2002243231A1
(en)
|
2000-11-21 |
2002-07-24 |
Wake Forest University |
Method of treating autoimmune diseases
|
CA2434269A1
(en)
|
2001-01-10 |
2002-07-18 |
The Government Of The United States Of America |
Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
|
AU2002236765A1
(en)
*
|
2001-01-16 |
2002-07-30 |
Glaxo Group Limited |
Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
ATE401395T1
(de)
|
2001-05-02 |
2008-08-15 |
Univ California |
Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
|
DE60237115D1
(de)
|
2001-05-30 |
2010-09-02 |
Univ Georgetown |
Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
MXPA04001612A
(es)
|
2001-08-21 |
2004-07-08 |
Fujisawa Pharmaceutical Co |
Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo.
|
WO2003017763A1
(en)
|
2001-08-24 |
2003-03-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
WO2003035843A2
(en)
|
2001-10-25 |
2003-05-01 |
Buck Institute For Age Research |
Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
|
US7354928B2
(en)
|
2001-11-01 |
2008-04-08 |
The Regents Of The University Of Michigan |
Small molecule inhibitors targeted at Bcl-2
|
WO2003053468A1
(en)
|
2001-12-21 |
2003-07-03 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
US20030134423A1
(en)
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
JP2005525345A
(ja)
|
2002-02-15 |
2005-08-25 |
スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ |
Trx媒介性疾患を処置する方法
|
CN1646558B
(zh)
|
2002-02-20 |
2010-05-12 |
国立大学法人九州工业大学 |
组蛋白脱乙酰酶抑制剂
|
EP2082737B1
(en)
|
2002-03-04 |
2014-12-31 |
Merck HDAC Research, LLC |
Methods of inducing terminal differentiation
|
US20040077591A1
(en)
|
2002-03-28 |
2004-04-22 |
The Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's Disease
|
JP2005521737A
(ja)
|
2002-04-05 |
2005-07-21 |
藤沢薬品工業株式会社 |
腎臓癌の治療のためのデプシペプチド
|
MXPA04010199A
(es)
|
2002-04-15 |
2005-07-05 |
Sloan Kettering Inst Cancer |
Terapia en combinacion para el tratamiento de cancer.
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
AU2003249309A1
(en)
|
2002-07-24 |
2004-02-09 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
DE60332367D1
(de)
|
2002-08-20 |
2010-06-10 |
Astellas Pharma Inc |
Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
|
ATE521354T1
(de)
|
2002-09-13 |
2011-09-15 |
Univ Virginia Commonwealth |
Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
|
SE0300098D0
(sv)
|
2003-01-15 |
2003-01-15 |
Forskarpatent I Syd Ab |
Use of cyclin D1 inhibitors
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
US20080233562A1
(en)
|
2003-02-19 |
2008-09-25 |
Astellas Pharma Inc. |
Method of Estimating Antitumor Effect of Histone Deacetylase Inhibitor
|
WO2004096289A1
(ja)
|
2003-04-25 |
2004-11-11 |
Fujisawa Pharmaceutical Co |
遺伝子導入効率増強剤
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
EP2238982B8
(en)
|
2003-06-27 |
2013-01-16 |
Astellas Pharma Inc. |
Therapeutic agent for soft tissue sarcoma
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
EP1663194B1
(en)
|
2003-08-26 |
2010-03-31 |
Merck HDAC Research, LLC |
Use of SAHA for treating mesothelioma
|
WO2005023179A2
(en)
|
2003-08-29 |
2005-03-17 |
Aton Pharma, Inc. |
Combination methods of treating cancer
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
WO2005027842A2
(en)
|
2003-09-18 |
2005-03-31 |
Combinatorx, Incorporated |
Combinations of drugs for the treatment of neoplasms
|
MXPA06003222A
(es)
*
|
2003-09-25 |
2006-05-22 |
Astellas Pharma Inc |
Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
CA2590257A1
(en)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
|
WO2005051430A1
(de)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
WO2005058298A2
(en)
|
2003-12-10 |
2005-06-30 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
US7951780B2
(en)
|
2004-02-25 |
2011-05-31 |
Astellas Pharma Inc. |
Antitumor agent
|
US20050187148A1
(en)
|
2004-02-25 |
2005-08-25 |
Yoshinori Naoe |
Antitumor agent
|
CA2557568C
(en)
|
2004-02-27 |
2014-05-27 |
Jane Trepel |
Pharmacodynamic assays using flow cytometry
|
GB0405349D0
(en)
|
2004-03-10 |
2004-04-21 |
Univ Birmingham |
Cancer therapy and medicaments therefor
|
ITMI20040876A1
(it)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
|
EP1591109B1
(en)
|
2004-04-30 |
2008-07-02 |
TopoTarget Germany AG |
Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
|
WO2005115149A2
(en)
|
2004-05-20 |
2005-12-08 |
Dow Agrosciences Llc |
Insectidal activity of a cyclic peptide
|
WO2005117930A2
(en)
|
2004-06-04 |
2005-12-15 |
Sloan-Kettering Institute For Cancer Research |
Use of thioredoxin measurements for diagnostics and treatments
|
WO2005123089A2
(en)
|
2004-06-10 |
2005-12-29 |
Kalypsys, Inc. |
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
CA2578384A1
(en)
|
2004-09-06 |
2006-03-16 |
Altana Pharma Ag |
Novel pyrazolopyrimidines
|
AU2005307814A1
(en)
|
2004-11-17 |
2006-05-26 |
The University Of Chicago |
Histone deacetylase inhibitors and methods of use
|
WO2006060382A2
(en)
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
|
WO2006060429A2
(en)
|
2004-12-03 |
2006-06-08 |
Novartis Ag |
Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
|
US20060128660A1
(en)
|
2004-12-10 |
2006-06-15 |
Wisconsin Alumni Research Foundation |
FK228 analogs and methods of making and using the same
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
EP1743654A1
(en)
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
WO2007040522A1
(en)
|
2005-09-30 |
2007-04-12 |
The Ohio State Research Foundation |
Antitumor agents
|
JP5319923B2
(ja)
*
|
2005-10-28 |
2013-10-16 |
協和発酵バイオ株式会社 |
濃縮晶析装置および方法
|
EP1957673A2
(en)
|
2005-11-10 |
2008-08-20 |
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services |
Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
|
CA2630216A1
(en)
|
2005-11-18 |
2007-05-31 |
Gloucester Pharmaceuticals, Inc. |
Metabolite derivatives of the hdac inhibitor fk228
|
CA2649877A1
(en)
|
2006-04-24 |
2007-12-21 |
Gloucester Pharmaceuticals |
Gemcitabine combination therapy
|
WO2007146730A2
(en)
|
2006-06-08 |
2007-12-21 |
Gloucester Pharmaceuticals |
Deacetylase inhibitor therapy
|
US20070292512A1
(en)
|
2006-06-09 |
2007-12-20 |
Merrion Research Ii Limited |
Solid Oral Dosage Form Containing an Enhancer
|
US7857804B2
(en)
|
2006-09-01 |
2010-12-28 |
Mccaffrey Timothy A |
Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
|
AU2007342030B2
(en)
|
2006-12-29 |
2013-08-15 |
Celgene Corporation |
Romidepsin-based treatments for cancer
|
AU2007342028B2
(en)
*
|
2006-12-29 |
2013-06-13 |
Celgene Corporation |
Purifiction of romidepsin
|
CN102276689A
(zh)
|
2011-05-09 |
2011-12-14 |
中国药科大学 |
组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用
|